25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Matinas BioPharma Holdings Inc
Buy, Hold or Sell?

Let's analyze Matinas BioPharma Holdings Inc together

I guess you are interested in Matinas BioPharma Holdings Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Matinas BioPharma Holdings Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Matinas BioPharma Holdings Inc

I send you an email if I find something interesting about Matinas BioPharma Holdings Inc.

1. Quick Overview

1.1. Quick analysis of Matinas BioPharma Holdings Inc (30 sec.)










1.2. What can you expect buying and holding a share of Matinas BioPharma Holdings Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
20.0%

What is your share worth?

Current worth
$3.10
Expected worth in 1 year
$6.10
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$3.00
Return On Investment
522.7%

For what price can you sell your share?

Current Price per Share
$0.57
Expected price per share
$0.478 - $2.95
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Matinas BioPharma Holdings Inc (5 min.)




Live pricePrice per Share (EOD)
$0.57
Intrinsic Value Per Share
$-39.51 - $-20.51
Total Value Per Share
$-36.41 - $-17.41

2.2. Growth of Matinas BioPharma Holdings Inc (5 min.)




Is Matinas BioPharma Holdings Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$15.7m$30m-$12.8m-75.1%

How much money is Matinas BioPharma Holdings Inc making?

Current yearPrevious yearGrowGrow %
Making money-$5.2m-$4.3m-$886.1k-16.8%
Net Profit Margin121.2%-124.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Matinas BioPharma Holdings Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#563 / 932

Most Revenue
#921 / 932

Most Profit
#410 / 932
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Matinas BioPharma Holdings Inc?

Welcome investor! Matinas BioPharma Holdings Inc's management wants to use your money to grow the business. In return you get a share of Matinas BioPharma Holdings Inc.

First you should know what it really means to hold a share of Matinas BioPharma Holdings Inc. And how you can make/lose money.

Speculation

The Price per Share of Matinas BioPharma Holdings Inc is $0.573. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Matinas BioPharma Holdings Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Matinas BioPharma Holdings Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.10. Based on the TTM, the Book Value Change Per Share is $0.75 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Matinas BioPharma Holdings Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.84-146.7%-1.04-181.2%-0.02-4.3%-0.23-40.1%-0.15-26.4%
Usd Book Value Change Per Share-0.65-114.0%0.75130.7%-0.02-3.1%0.1425.0%0.0712.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.69119.9%0.4782.3%
Usd Total Gains Per Share-0.65-114.0%0.75130.7%-0.02-3.1%0.83144.9%0.5595.2%
Usd Price Per Share3.54-1.05-0.37-0.89-0.95-
Price to Earnings Ratio-1.05--0.30--4.12--6.03--4.92-
Price-to-Total Gains Ratio-5.42--1.37--25.51--15.14--14.96-
Price to Book Ratio1.14-0.33-2.53-2.93-5.56-
Price-to-Total Gains Ratio-5.42--1.37--25.51--15.14--14.96-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.573
Number of shares1745
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.69
Usd Book Value Change Per Share0.750.14
Usd Total Gains Per Share0.750.83
Gains per Quarter (1745 shares)1,306.691,448.38
Gains per Year (1745 shares)5,226.785,793.52
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
105227521747959985784
2010454104449591199611578
30156801567114386299417372
40209072089819182399223166
50261342612523977499028960
60313613135228773598834754
70365873657933568698640548
80418144180638364798446342
90470414703343159898252136
100522685226047955998157930

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%2.038.00.05.0%2.042.00.04.5%
Book Value Change Per Share2.02.00.050.0%2.010.00.016.7%4.016.00.020.0%10.029.01.025.0%11.032.01.025.0%
Dividend per Share0.00.04.00.0%1.00.011.08.3%6.00.014.030.0%8.00.032.020.0%8.00.036.018.2%
Total Gains per Share2.02.00.050.0%2.010.00.016.7%5.015.00.025.0%13.027.00.032.5%14.030.00.031.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Matinas BioPharma Holdings Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.6530.749-187%-0.018-97%0.143-557%0.074-985%
Book Value Per Share--3.1023.376-8%0.138+2140%0.872+256%0.505+514%
Current Ratio--5.5285.749-4%9.598-42%13.367-59%9.292-41%
Debt To Asset Ratio--0.2330.353-34%0.184+27%0.182+28%0.219+7%
Debt To Equity Ratio--0.3040.833-64%0.226+34%0.299+2%0.330-8%
Dividend Per Share----0%0.000-100%0.687-100%0.472-100%
Enterprise Value--24004909.2001730388.698+1287%96185980.115-75%167206839.676-86%129700999.096-81%
Eps---0.840-1.039+24%-0.024-97%-0.230-73%-0.151-82%
Ev To Ebitda Ratio---1.451-0.178-88%-3.969+174%-6.791+368%-6.855+373%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---0.688-0.833+21%-0.018-97%-0.308-55%-0.284-59%
Free Cash Flow To Equity Per Share---0.701-0.382-45%-0.018-97%-0.203-71%-0.208-70%
Gross Profit Margin--1.0001.032-3%1.0000%1.006-1%1.0030%
Intrinsic Value_10Y_max---20.510--------
Intrinsic Value_10Y_min---39.512--------
Intrinsic Value_1Y_max---1.270--------
Intrinsic Value_1Y_min---1.650--------
Intrinsic Value_3Y_max---4.414--------
Intrinsic Value_3Y_min---6.987--------
Intrinsic Value_5Y_max---8.280--------
Intrinsic Value_5Y_min---14.508--------
Market Cap2914839.540-518%18007909.2005322888.698+238%79256480.115-77%137693775.776-87%111893090.096-84%
Net Profit Margin---1.212-100%-1.2490%-2.7320%-23.6820%
Operating Margin---1.356-100%-2.8930%-6.8170%-26.7640%
Operating Ratio----1.3430%3.936-100%2.657-100%44.752-100%
Pb Ratio0.185-518%1.1410.334+242%2.530-55%2.932-61%5.560-79%
Pe Ratio-0.170+84%-1.053-0.300-72%-4.121+291%-6.033+473%-4.920+367%
Price Per Share0.573-518%3.5401.046+238%0.365+870%0.889+298%0.955+271%
Price To Free Cash Flow Ratio-0.208+84%-1.286-0.368-71%-5.562+332%-8.557+565%-8.555+565%
Price To Total Gains Ratio-0.877+84%-5.418-1.369-75%-25.506+371%-15.136+179%-14.957+176%
Quick Ratio--5.3187.954-33%14.487-63%21.180-75%13.073-59%
Return On Assets---0.208-0.205-1%-0.131-37%-0.120-42%-0.185-11%
Return On Equity---0.271-0.312+15%-0.162-40%-0.156-43%-0.254-6%
Total Gains Per Share---0.6530.749-187%-0.018-97%0.830-179%0.546-220%
Usd Book Value--15779000.00017171500.000-8%30066500.000-48%43686143.250-64%28164341.575-44%
Usd Book Value Change Per Share---0.6530.749-187%-0.018-97%0.143-557%0.074-985%
Usd Book Value Per Share--3.1023.376-8%0.138+2140%0.872+256%0.505+514%
Usd Dividend Per Share----0%0.000-100%0.687-100%0.472-100%
Usd Enterprise Value--24004909.2001730388.698+1287%96185980.115-75%167206839.676-86%129700999.096-81%
Usd Eps---0.840-1.039+24%-0.024-97%-0.230-73%-0.151-82%
Usd Free Cash Flow---3500000.000-4238500.000+21%-3814494.750+9%-24543402.200+601%-26858073.950+667%
Usd Free Cash Flow Per Share---0.688-0.833+21%-0.018-97%-0.308-55%-0.284-59%
Usd Free Cash Flow To Equity Per Share---0.701-0.382-45%-0.018-97%-0.203-71%-0.208-70%
Usd Market Cap2914839.540-518%18007909.2005322888.698+238%79256480.115-77%137693775.776-87%111893090.096-84%
Usd Price Per Share0.573-518%3.5401.046+238%0.365+870%0.889+298%0.955+271%
Usd Profit---4275000.000-5283000.000+24%-4396891.250+3%-5195167.750+22%-4115673.600-4%
Usd Revenue----274000.0000%539750.000-100%162827.700-100%149440.400-100%
Usd Total Gains Per Share---0.6530.749-187%-0.018-97%0.830-179%0.546-220%
 EOD+3 -5MRQTTM+16 -19YOY+9 -275Y+9 -2810Y+9 -28

3.3 Fundamental Score

Let's check the fundamental score of Matinas BioPharma Holdings Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.170
Price to Book Ratio (EOD)Between0-10.185
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than15.318
Current Ratio (MRQ)Greater than15.528
Debt to Asset Ratio (MRQ)Less than10.233
Debt to Equity Ratio (MRQ)Less than10.304
Return on Equity (MRQ)Greater than0.15-0.271
Return on Assets (MRQ)Greater than0.05-0.208
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Matinas BioPharma Holdings Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.583
Ma 20Greater thanMa 500.602
Ma 50Greater thanMa 1000.608
Ma 100Greater thanMa 2002.029
OpenGreater thanClose0.593
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Matinas BioPharma Holdings Inc

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

Fundamental data was last updated by Penke on 2025-01-07 14:04:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Matinas BioPharma Holdings Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Matinas BioPharma Holdings Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Matinas BioPharma Holdings Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM121.2%-121.2%
TTM121.2%YOY-124.9%+246.1%
TTM121.2%5Y-273.2%+394.4%
5Y-273.2%10Y-2,368.2%+2,095.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--104.6%+104.6%
TTM121.2%-211.9%+333.1%
YOY-124.9%-209.8%+84.9%
5Y-273.2%-354.1%+80.9%
10Y-2,368.2%-489.2%-1,879.0%
4.3.1.2. Return on Assets

Shows how efficient Matinas BioPharma Holdings Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Matinas BioPharma Holdings Inc to the Biotechnology industry mean.
  • -20.8% Return on Assets means that Matinas BioPharma Holdings Inc generated $-0.21 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Matinas BioPharma Holdings Inc:

  • The MRQ is -20.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -20.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-20.8%TTM-20.5%-0.3%
TTM-20.5%YOY-13.1%-7.4%
TTM-20.5%5Y-12.0%-8.5%
5Y-12.0%10Y-18.5%+6.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.8%-12.6%-8.2%
TTM-20.5%-13.0%-7.5%
YOY-13.1%-12.4%-0.7%
5Y-12.0%-13.7%+1.7%
10Y-18.5%-15.8%-2.7%
4.3.1.3. Return on Equity

Shows how efficient Matinas BioPharma Holdings Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Matinas BioPharma Holdings Inc to the Biotechnology industry mean.
  • -27.1% Return on Equity means Matinas BioPharma Holdings Inc generated $-0.27 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Matinas BioPharma Holdings Inc:

  • The MRQ is -27.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -31.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-27.1%TTM-31.2%+4.1%
TTM-31.2%YOY-16.2%-15.0%
TTM-31.2%5Y-15.6%-15.6%
5Y-15.6%10Y-25.4%+9.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-27.1%-16.8%-10.3%
TTM-31.2%-17.8%-13.4%
YOY-16.2%-16.4%+0.2%
5Y-15.6%-20.6%+5.0%
10Y-25.4%-21.3%-4.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Matinas BioPharma Holdings Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Matinas BioPharma Holdings Inc is operating .

  • Measures how much profit Matinas BioPharma Holdings Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Matinas BioPharma Holdings Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Matinas BioPharma Holdings Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM135.6%-135.6%
TTM135.6%YOY-289.3%+424.9%
TTM135.6%5Y-681.7%+817.3%
5Y-681.7%10Y-2,676.4%+1,994.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--201.1%+201.1%
TTM135.6%-321.1%+456.7%
YOY-289.3%-224.0%-65.3%
5Y-681.7%-371.8%-309.9%
10Y-2,676.4%-506.8%-2,169.6%
4.3.2.2. Operating Ratio

Measures how efficient Matinas BioPharma Holdings Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Matinas BioPharma Holdings Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1.343+1.343
TTM-1.343YOY3.936-5.279
TTM-1.3435Y2.657-4.000
5Y2.65710Y44.752-42.095
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.171-2.171
TTM-1.3433.241-4.584
YOY3.9363.239+0.697
5Y2.6574.839-2.182
10Y44.7526.444+38.308
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Matinas BioPharma Holdings Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Matinas BioPharma Holdings Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.53 means the company has $5.53 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Matinas BioPharma Holdings Inc:

  • The MRQ is 5.528. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.749. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.528TTM5.749-0.221
TTM5.749YOY9.598-3.850
TTM5.7495Y13.367-7.618
5Y13.36710Y9.292+4.075
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.5283.609+1.919
TTM5.7493.842+1.907
YOY9.5984.609+4.989
5Y13.3675.917+7.450
10Y9.2926.176+3.116
4.4.3.2. Quick Ratio

Measures if Matinas BioPharma Holdings Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Matinas BioPharma Holdings Inc to the Biotechnology industry mean.
  • A Quick Ratio of 5.32 means the company can pay off $5.32 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Matinas BioPharma Holdings Inc:

  • The MRQ is 5.318. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 7.954. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.318TTM7.954-2.636
TTM7.954YOY14.487-6.533
TTM7.9545Y21.180-13.226
5Y21.18010Y13.073+8.107
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.3183.011+2.307
TTM7.9543.349+4.605
YOY14.4874.298+10.189
5Y21.1805.936+15.244
10Y13.0736.457+6.616
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Matinas BioPharma Holdings Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Matinas BioPharma Holdings Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Matinas BioPharma Holdings Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.23 means that Matinas BioPharma Holdings Inc assets are financed with 23.3% credit (debt) and the remaining percentage (100% - 23.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Matinas BioPharma Holdings Inc:

  • The MRQ is 0.233. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.353. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.233TTM0.353-0.120
TTM0.353YOY0.184+0.170
TTM0.3535Y0.182+0.171
5Y0.18210Y0.219-0.037
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2330.342-0.109
TTM0.3530.342+0.011
YOY0.1840.312-0.128
5Y0.1820.365-0.183
10Y0.2190.385-0.166
4.5.4.2. Debt to Equity Ratio

Measures if Matinas BioPharma Holdings Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Matinas BioPharma Holdings Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 30.4% means that company has $0.30 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Matinas BioPharma Holdings Inc:

  • The MRQ is 0.304. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.833. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.304TTM0.833-0.529
TTM0.833YOY0.226+0.607
TTM0.8335Y0.299+0.535
5Y0.29910Y0.330-0.031
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3040.393-0.089
TTM0.8330.430+0.403
YOY0.2260.383-0.157
5Y0.2990.441-0.142
10Y0.3300.490-0.160
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Matinas BioPharma Holdings Inc generates.

  • Above 15 is considered overpriced but always compare Matinas BioPharma Holdings Inc to the Biotechnology industry mean.
  • A PE ratio of -1.05 means the investor is paying $-1.05 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Matinas BioPharma Holdings Inc:

  • The EOD is -0.170. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.053. Based on the earnings, the company is expensive. -2
  • The TTM is -0.300. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.170MRQ-1.053+0.883
MRQ-1.053TTM-0.300-0.753
TTM-0.300YOY-4.121+3.821
TTM-0.3005Y-6.033+5.733
5Y-6.03310Y-4.920-1.113
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.170-2.204+2.034
MRQ-1.053-2.733+1.680
TTM-0.300-3.241+2.941
YOY-4.121-3.335-0.786
5Y-6.033-6.499+0.466
10Y-4.920-6.785+1.865
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Matinas BioPharma Holdings Inc:

  • The EOD is -0.208. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.286. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.368. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.208MRQ-1.286+1.078
MRQ-1.286TTM-0.368-0.919
TTM-0.368YOY-5.562+5.194
TTM-0.3685Y-8.557+8.189
5Y-8.55710Y-8.555-0.002
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.208-3.043+2.835
MRQ-1.286-3.763+2.477
TTM-0.368-4.095+3.727
YOY-5.562-4.518-1.044
5Y-8.557-8.387-0.170
10Y-8.555-9.433+0.878
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Matinas BioPharma Holdings Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.14 means the investor is paying $1.14 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Matinas BioPharma Holdings Inc:

  • The EOD is 0.185. Based on the equity, the company is cheap. +2
  • The MRQ is 1.141. Based on the equity, the company is underpriced. +1
  • The TTM is 0.334. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.185MRQ1.141-0.957
MRQ1.141TTM0.334+0.807
TTM0.334YOY2.530-2.196
TTM0.3345Y2.932-2.598
5Y2.93210Y5.560-2.629
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.1851.906-1.721
MRQ1.1412.276-1.135
TTM0.3342.473-2.139
YOY2.5302.459+0.071
5Y2.9323.669-0.737
10Y5.5604.237+1.323
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Matinas BioPharma Holdings Inc.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets20,577
Total Liabilities4,798
Total Stockholder Equity15,779
 As reported
Total Liabilities 4,798
Total Stockholder Equity+ 15,779
Total Assets = 20,577

Assets

Total Assets20,577
Total Current Assets11,741
Long-term Assets8,836
Total Current Assets
Cash And Cash Equivalents 10,295
Short-term Investments 500
Other Current Assets 946
Total Current Assets  (as reported)11,741
Total Current Assets  (calculated)11,741
+/-0
Long-term Assets
Property Plant Equipment 2,635
Goodwill 1,336
Long-term Assets Other 4,865
Long-term Assets  (as reported)8,836
Long-term Assets  (calculated)8,836
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,124
Long-term Liabilities2,674
Total Stockholder Equity15,779
Total Current Liabilities
Short-term Debt 738
Accounts payable 349
Other Current Liabilities 1,037
Total Current Liabilities  (as reported)2,124
Total Current Liabilities  (calculated)2,124
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)2,674
Long-term Liabilities  (calculated)0
+/- 2,674
Total Stockholder Equity
Common Stock1
Retained Earnings -191,391
Other Stockholders Equity 207,169
Total Stockholder Equity (as reported)15,779
Total Stockholder Equity (calculated)15,779
+/-0
Other
Cash and Short Term Investments 10,795
Common Stock Shares Outstanding 5,038
Liabilities and Stockholders Equity 20,577
Net Debt -7,224
Net Working Capital 9,617
Short Long Term Debt Total 3,071



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-31
> Total Assets 
0
0
0
11,334
9,327
7,363
5,789
3,361
9,798
11,862
9,869
8,406
6,746
5,565
11,307
9,816
22,032
17,800
16,524
14,424
11,489
16,044
14,412
19,943
19,943
48,215
44,816
40,240
84,113
79,087
74,806
70,967
72,351
69,971
66,985
61,326
55,785
52,416
47,546
44,819
38,262
34,025
29,791
65,578
19,610
24,365
20,577
20,57724,36519,61065,57829,79134,02538,26244,81947,54652,41655,78561,32666,98569,97172,35170,96774,80679,08784,11340,24044,81648,21519,94319,94314,41216,04411,48914,42416,52417,80022,0329,81611,3075,5656,7468,4069,86911,8629,7983,3615,7897,3639,32711,334000
   > Total Current Assets 
0
0
0
10,925
8,646
6,686
5,115
2,805
4,840
6,880
4,885
3,559
1,912
774
6,529
4,565
16,793
11,739
10,173
7,964
4,894
9,343
7,525
13,085
13,085
37,426
34,251
29,923
73,989
69,209
65,203
61,555
63,136
60,939
56,481
50,993
45,119
41,924
37,099
34,532
28,206
24,000
19,989
15,543
10,289
15,285
11,741
11,74115,28510,28915,54319,98924,00028,20634,53237,09941,92445,11950,99356,48160,93963,13661,55565,20369,20973,98929,92334,25137,42613,08513,0857,5259,3434,8947,96410,17311,73916,7934,5656,5297741,9123,5594,8856,8804,8402,8055,1156,6868,64610,925000
       Cash And Cash Equivalents 
0
0
0
10,840
8,558
6,647
5,007
2,591
4,617
6,605
4,363
3,227
1,673
578
6,220
4,105
15,835
11,266
9,001
7,307
4,263
8,903
6,632
12,447
12,447
36,831
32,665
22,170
10,078
14,904
7,051
12,432
23,383
30,352
24,923
21,030
19,328
10,399
11,176
6,830
5,739
9,743
6,407
4,837
1,121
4,216
10,295
10,2954,2161,1214,8376,4079,7435,7396,83011,17610,39919,32821,03024,92330,35223,38312,4327,05114,90410,07822,17032,66536,83112,44712,4476,6328,9034,2637,3079,00111,26615,8354,1056,2205781,6733,2274,3636,6054,6172,5915,0076,6478,55810,840000
       Short-term Investments 
0
0
0
0
0
0
0
100
100
100
100
100
100
56
56
156
155
155
155
155
155
100
200
0
0
0
0
5,605
61,090
53,054
55,720
46,247
37,284
29,490
28,907
28,592
24,542
28,104
21,875
21,933
19,118
12,770
11,809
8,969
7,039
10,097
500
50010,0977,0398,96911,80912,77019,11821,93321,87528,10424,54228,59228,90729,49037,28446,24755,72053,05461,0905,605000020010015515515515515515656561001001001001001000000000
       Net Receivables 
0
0
0
0
0
0
0
0
30
60
80
0
0
0
0
0
0
0
0
0
0
90
0
0
0
0
0
0
0
0
0
650
1,300
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000001,30065000000000090000000000080603000000000
       Other Current Assets 
0
0
0
84
0
38
108
214
194
215
442
332
238
195
310
460
959
473
1,173
657
631
350
892
639
639
595
1,586
2,148
2,821
1,251
2,432
2,876
2,469
1,096
2,651
29,964
1,249
3,422
4,048
5,719
3,299
1,437
1,723
3,524
2,179
972
946
9469722,1793,5241,7231,4373,2995,7194,0483,4221,24929,9642,6511,0962,4692,8762,4321,2512,8212,1481,5865956396398923506316571,17347395946031019523833244221519421410838084000
   > Long-term Assets 
0
0
0
409
681
678
674
556
4,957
4,982
4,984
4,847
4,834
4,791
4,778
5,251
5,238
6,061
6,350
6,460
6,596
6,701
6,887
6,858
6,858
10,789
10,565
10,317
10,124
9,878
9,603
9,412
9,215
9,032
10,504
10,333
10,666
10,491
10,447
10,287
10,056
10,025
9,802
50,035
9,321
9,080
8,836
8,8369,0809,32150,0359,80210,02510,05610,28710,44710,49110,66610,33310,5049,0329,2159,4129,6039,87810,12410,31710,56510,7896,8586,8586,8876,7016,5966,4606,3506,0615,2385,2514,7784,7914,8344,8474,9844,9824,957556674678681409000
       Property Plant Equipment 
0
0
0
93
365
362
357
340
339
363
366
378
365
382
369
356
344
1,171
1,461
1,570
1,706
1,811
2,097
2,043
2,043
5,949
5,825
5,628
5,435
5,239
5,050
4,859
4,661
4,479
5,950
5,779
6,112
5,938
5,893
5,734
5,503
5,472
5,249
5,008
4,768
4,527
2,635
2,6354,5274,7685,0085,2495,4725,5035,7345,8935,9386,1125,7795,9504,4794,6614,8595,0505,2395,4355,6285,8255,9492,0432,0432,0971,8111,7061,5701,4611,17134435636938236537836636333934035736236593000
       Goodwill 
0
0
0
0
0
0
0
1,336
1,385
1,385
1,385
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,336
1,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3361,3851,3851,3851,3360000000
       Long Term Investments 
0
0
0
0
316
316
316
216
216
216
217
115
115
55
55
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000055551151152172162162163163163160000
       Intangible Assets 
0
0
0
0
0
0
0
0
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
3,017
0
03,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,0173,01700000000
       Other Assets 
0
0
0
0
316
316
316
216
4,618
4,619
4,619
4,469
4,468
4,409
4,409
4,895
4,895
4,890
4,890
4,890
3,553
3,553
3,453
3,478
486
3,503
3,403
3,353
3,353
3,303
3,217
3,217
3,217
3,217
3,217
3,217
3,217
3,217
3,217
3,217
0
3,217
0
0
0
0
0
000003,21703,2173,2173,2173,2173,2173,2173,2173,2173,2173,2173,3033,3533,3533,4033,5034863,4783,4533,5533,5534,8904,8904,8904,8954,8954,4094,4094,4684,4694,6194,6194,6182163163163160000
> Total Liabilities 
0
0
0
859
717
906
1,043
1,134
3,405
3,233
2,908
2,334
2,525
2,567
2,585
2,666
3,172
2,592
3,739
3,742
3,056
3,517
4,112
3,802
3,802
7,797
6,835
7,189
6,510
6,262
6,601
7,237
5,794
7,068
8,731
8,833
8,103
9,567
8,927
8,182
5,637
6,171
6,641
46,332
5,052
5,262
4,798
4,7985,2625,05246,3326,6416,1715,6378,1828,9279,5678,1038,8338,7317,0685,7947,2376,6016,2626,5107,1896,8357,7973,8023,8024,1123,5173,0563,7423,7392,5923,1722,6662,5852,5672,5252,3342,9083,2333,4051,1341,043906717859000
   > Total Current Liabilities 
0
0
0
859
673
872
1,021
1,118
1,308
1,136
873
1,129
1,320
1,342
1,361
1,445
1,953
1,335
1,883
2,225
1,030
1,490
2,639
2,840
2,840
3,464
2,622
3,097
2,543
2,408
2,838
3,568
2,221
3,591
4,099
4,349
3,768
5,382
4,902
4,286
1,896
2,589
3,229
2,622
1,998
2,392
2,124
2,1242,3921,9982,6223,2292,5891,8964,2864,9025,3823,7684,3494,0993,5912,2213,5682,8382,4082,5433,0972,6223,4642,8402,8402,6391,4901,0302,2251,8831,3351,9531,4451,3611,3421,3201,1298731,1361,3081,1181,021872673859000
       Short-term Debt 
0
0
0
0
45
44
44
44
55
44
32
11
0
10
199
128
57
19
317
197
94
53
403
200
283
466
474
479
484
478
450
422
394
378
543
560
576
591
548
569
589
613
637
1,322
686
1,424
738
7381,4246861,3226376135895695485915765605433783944224504784844794744662832004035394197317195712819910011324455444444450000
       Short Long Term Debt 
0
0
0
0
0
0
0
60
0
0
0
11
0
10
199
144
57
70
365
27
52
53
83
83
80
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000808383535227365705714419910011000600000000
       Accounts payable 
0
0
0
397
242
281
212
271
467
746
282
498
621
476
209
476
1,247
453
342
583
474
497
303
2,557
296
548
686
679
953
495
373
350
422
450
662
938
1,352
497
657
618
516
604
835
514
473
238
349
3492384735148356045166186574971,3529386624504223503734959536796865482962,5573034974745833424531,247476209476621498282746467271212281242397000
       Other Current Liabilities 
0
0
0
462
45
44
44
44
45
381
581
11
699
866
962
851
483
743
1,149
1,415
-1
0
0
1,174
2,344
2,916
1,937
1,839
906
1,235
1,911
2,152
1,220
1,923
1,662
1,919
1,139
2,198
2,289
2,378
791
1,372
1,757
786
839
730
1,037
1,0377308397861,7571,3727912,3782,2892,1981,1391,9191,6621,9231,2202,1521,9111,2359061,8391,9372,9162,3441,17400-11,4151,149743483851962866699115813814544444445462000
   > Long-term Liabilities 
0
0
0
0
44
34
22
15
2,097
2,097
2,035
1,205
1,205
1,226
1,224
1,222
1,219
1,257
1,856
1,517
2,026
2,028
1,473
962
962
4,333
4,213
4,092
3,967
3,854
3,763
3,669
3,573
3,476
4,632
4,484
4,335
4,185
4,025
3,896
3,741
3,582
3,412
43,710
3,054
2,870
2,674
2,6742,8703,05443,7103,4123,5823,7413,8964,0254,1854,3354,4844,6323,4763,5733,6693,7633,8543,9674,0924,2134,3339629621,4732,0282,0261,5171,8561,2571,2191,2221,2241,2261,2051,2052,0352,0972,097152234440000
       Long term Debt Total 
0
0
0
0
44
34
22
15
0
0
0
0
0
21
0
0
0
0
0
0
0
0
0
108
89
73
62
55
47
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000047556273891080000000002100000152234440000
       Other Liabilities 
0
0
0
0
44
34
22
0
843
844
782
1,205
0
0
0
1,205
1,205
1,205
603
601
1,910
1,924
1,350
854
341
341
341
341
341
341
341
341
341
341
341
341
341
341
341
341
0
341
0
0
0
0
0
0000034103413413413413413413413413413413413413413413413418541,3501,9241,9106016031,2051,2051,2050001,20578284484302234440000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
1,205
0
0
0
3,017
0
1,205
1,205
3,017
1,205
3,017
3,017
3,017
3,017
3,017
3,017
854
3,017
3,017
3,017
3,017
3,017
3,017
341
3,017
341
3,017
341
341
341
341
341
341
341
341
0
0
0
0
0
000003413413413413413413413413,0173413,0173413,0173,0173,0173,0173,0173,0178543,0173,0173,0173,0173,0173,0171,2053,0171,2051,20503,0170001,2050000000
> Total Stockholder Equity
0
0
0
10,475
8,610
6,457
4,746
2,228
6,393
8,629
6,961
6,072
4,220
2,997
8,722
7,150
18,860
15,208
12,785
10,682
8,434
12,527
10,300
16,142
16,142
40,418
37,981
33,051
77,603
72,825
68,205
63,731
66,556
62,904
58,254
52,493
47,682
42,849
38,619
36,637
32,625
27,854
23,150
19,246
14,558
19,103
15,779
15,77919,10314,55819,24623,15027,85432,62536,63738,61942,84947,68252,49358,25462,90466,55663,73168,20572,82577,60333,05137,98140,41816,14216,14210,30012,5278,43410,68212,78515,20818,8607,1508,7222,9974,2206,0726,9618,6296,3932,2284,7466,4578,61010,475000
   Common Stock
0
0
0
3
3
3
3
3
5
6
6
6
6
6
6
6
9
9
9
9
9
9
10
11
11
14
16
16
20
20
20
20
20
21
22
22
22
22
22
22
22
22
22
22
22
25
1
12522222222222222222222222120202020201616141111109999996666666533333000
   Retained Earnings Total Equity00000-164,204-158,144-152,631-148,997-143,535-137,612-131,634-124,935-118,098-112,464-107,507-101,166-95,717-89,423-84,378-78,805-73,813-69,995-65,94500000000-33,288-27,056-25,432-23,187-21,181-19,026-16,622-14,052-11,007-8,396-5,9700000
   Accumulated Other Comprehensive Income 
0
0
0
-1
0
0
-66
-43
-43
0
0
-87
-100
-114
-127
-140
-152
-165
-196
-241
-288
-341
-397
-439
-439
-464
-509
-1
522
478
364
228
136
51
-2
-145
-629
-754
-936
-824
-595
-514
-359
-221
-134
-51
0
0-51-134-221-359-514-595-824-936-754-629-145-251136228364478522-1-509-464-439-439-397-341-288-241-196-165-152-140-127-114-100-8700-43-43-6600-1000
   Capital Surplus 
0
0
0
0
14,576
14,850
15,750
16,276
23,010
27,650
28,136
29,254
29,647
30,047
35,918
0
0
0
0
0
0
0
0
72,295
103,284
104,601
112,746
113,428
162,520
164,080
165,024
167,192
175,190
180,929
183,169
184,251
185,902
187,116
188,529
190,070
191,342
192,550
0
0
0
0
0
00000192,550191,342190,070188,529187,116185,902184,251183,169180,929175,190167,192165,024164,080162,520113,428112,746104,601103,28472,2950000000035,91830,04729,64729,25428,13627,65023,01016,27615,75014,85014,5760000
   Treasury Stock00000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
14,303
14,576
14,850
15,816
16,319
23,010
27,650
28,136
29,341
29,747
30,161
36,045
36,378
52,630
53,210
54,882
56,471
58,494
59,125
61,324
0
72,734
105,065
113,255
113,428
162,520
164,080
165,024
167,192
175,190
180,929
183,169
184,251
185,902
187,116
188,529
190,070
191,342
192,550
193,746
195,018
196,067
206,245
207,169
207,169206,245196,067195,018193,746192,550191,342190,070188,529187,116185,902184,251183,169180,929175,190167,192165,024164,080162,520113,428113,255105,06572,734061,32459,12558,49456,47154,88253,21052,63036,37836,04530,16129,74729,34128,13627,65023,01016,31915,81614,85014,57614,303000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue1,096
Cost of Revenue-14,489
Gross Profit-13,393-13,393
 
Operating Income (+$)
Gross Profit-13,393
Operating Expense-24,862
Operating Income-23,766-38,255
 
Operating Expense (+$)
Research Development14,489
Selling General Administrative10,373
Selling And Marketing Expenses941
Operating Expense24,86225,803
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-23,766
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-22,942-24,590
EBIT - interestExpense = -23,766
-22,169
-22,942
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-23,766-22,942
Earnings Before Interest and Taxes (EBITDA)-22,825
 
After tax Income (+$)
Income Before Tax-22,942
Tax Provision-0
Net Income From Continuing Ops-21,262-22,942
Net Income-22,942
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses24,862
Total Other Income/Expenses Net8240
 

Technical Analysis of Matinas BioPharma Holdings Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Matinas BioPharma Holdings Inc. The general trend of Matinas BioPharma Holdings Inc is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Matinas BioPharma Holdings Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Matinas BioPharma Holdings Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.08 < 1.43 < 2.95.

The bearish price targets are: 0.5 > 0.5 > 0.478.

Tweet this
Matinas BioPharma Holdings Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Matinas BioPharma Holdings Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Matinas BioPharma Holdings Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Matinas BioPharma Holdings Inc. The current macd is -0.04126449.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Matinas BioPharma Holdings Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Matinas BioPharma Holdings Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Matinas BioPharma Holdings Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Matinas BioPharma Holdings Inc Daily Moving Average Convergence/Divergence (MACD) ChartMatinas BioPharma Holdings Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Matinas BioPharma Holdings Inc. The current adx is 43.11.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Matinas BioPharma Holdings Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Matinas BioPharma Holdings Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Matinas BioPharma Holdings Inc. The current sar is 1.29742497.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Matinas BioPharma Holdings Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Matinas BioPharma Holdings Inc. The current rsi is 44.58. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Matinas BioPharma Holdings Inc Daily Relative Strength Index (RSI) ChartMatinas BioPharma Holdings Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Matinas BioPharma Holdings Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Matinas BioPharma Holdings Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Matinas BioPharma Holdings Inc Daily Stochastic Oscillator ChartMatinas BioPharma Holdings Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Matinas BioPharma Holdings Inc. The current cci is -23.52765414.

Matinas BioPharma Holdings Inc Daily Commodity Channel Index (CCI) ChartMatinas BioPharma Holdings Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Matinas BioPharma Holdings Inc. The current cmo is -8.52820028.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Matinas BioPharma Holdings Inc Daily Chande Momentum Oscillator (CMO) ChartMatinas BioPharma Holdings Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Matinas BioPharma Holdings Inc. The current willr is -90.0210084.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Matinas BioPharma Holdings Inc Daily Williams %R ChartMatinas BioPharma Holdings Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Matinas BioPharma Holdings Inc.

Matinas BioPharma Holdings Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Matinas BioPharma Holdings Inc. The current atr is 0.14132542.

Matinas BioPharma Holdings Inc Daily Average True Range (ATR) ChartMatinas BioPharma Holdings Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Matinas BioPharma Holdings Inc. The current obv is 14,972,080.

Matinas BioPharma Holdings Inc Daily On-Balance Volume (OBV) ChartMatinas BioPharma Holdings Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Matinas BioPharma Holdings Inc. The current mfi is 93.84.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Matinas BioPharma Holdings Inc Daily Money Flow Index (MFI) ChartMatinas BioPharma Holdings Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Matinas BioPharma Holdings Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-08-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-27MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-03ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-09-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-23MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-09-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-02BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-07RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-10-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-10-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-17BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-10-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-21ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-31ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-04STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-08MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-12-02MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-12-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-12-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-01-02RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-01-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-07STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-01-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-17STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Matinas BioPharma Holdings Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Matinas BioPharma Holdings Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.583
Ma 20Greater thanMa 500.602
Ma 50Greater thanMa 1000.608
Ma 100Greater thanMa 2002.029
OpenGreater thanClose0.593
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Matinas BioPharma Holdings Inc with someone you think should read this too:
  • Are you bullish or bearish on Matinas BioPharma Holdings Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Matinas BioPharma Holdings Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Matinas BioPharma Holdings Inc

I send you an email if I find something interesting about Matinas BioPharma Holdings Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Matinas BioPharma Holdings Inc.

Receive notifications about Matinas BioPharma Holdings Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.